Multimodal treatment of advanced renal cancer in 2017

References

• Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906.
   PubMed Web of Science ®Google Scholar
• Bergström A, Hsieh CC, Lindblad P, et al. Obesity and renal cell cancer–a quantitative review. Br J Cancer. 2001;85(7):984.
   PubMed Web of Science ®Google Scholar
• Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med (Lond). 2002;52(3):157–164.
   PubMed Web of Science ®Google Scholar
• Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011;171(16):1487–1493.
   PubMedGoogle Scholar
• Gonzalez HC, Lamerato L, Rogers CG, et al. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60(6):1820–1824.
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257.
   PubMed Web of Science ®Google Scholar
• Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21(1):81–90.
   PubMed Web of Science ®Google Scholar
• Petejova N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):183–194.
   PubMed Web of Science ®Google Scholar
• Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics. 2001;21:S237–S254.
   PubMed Web of Science ®Google Scholar
• McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–584.
   PubMed Web of Science ®Google Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799.
   PubMed Web of Science ®Google Scholar
• Otaibi MA, Tanguay S. Locally advanced renal cell carcinoma. Can Urol Assoc J. 2007;1(2 Suppl):S55–61.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Perrotte P, Zini L, et al. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU Int. 2009;104(6):795–799.
   PubMed Web of Science ®Google Scholar
• Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–3322.
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395–2400.
   PubMed Web of Science ®Google Scholar
• Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19(2):425–431.
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21(7):1214–1222.
   PubMed Web of Science ®Google Scholar
• Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21(16):3133–3140.
   PubMed Web of Science ®Google Scholar
• Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008–2016.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–2254.
   PubMed Web of Science ®Google Scholar
• Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med. 2016;4(Suppl 1):S14.
   PubMedGoogle Scholar
• Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;JCO2017735324 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Chamie K, Donin NM, Klöpfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3(7):913–920.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa- 2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet. 2001;358(9286):966–970.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–1076.
   PubMed Web of Science ®Google Scholar
• Pantuck A, Belldegrun A, Figlin R. Nephrectomy and interleukin-2 for metastatic renal cell carcinoma. N Engl J Med. 2001;345(23):1711–1712.
   PubMed Web of Science ®Google Scholar
• You D, Jeong IG, Ahn JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–59.
   PubMed Web of Science ®Google Scholar
• Richey SL, Culp SH, Jonasch E, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011;22(5):1048–1053.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–66.
   PubMed Web of Science ®Google Scholar
• Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58(6):819–828.
   PubMed Web of Science ®Google Scholar
• Abel E, Culp S, Tannir N, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011;60(6):1273–1279.
   PubMed Web of Science ®Google Scholar
• Cost N, Delacroix S Jr, Sleeper J, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59(6):912–918.
   PubMed Web of Science ®Google Scholar
• Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–2882.
   PubMed Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–2266.
   PubMed Web of Science ®Google Scholar
• Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002;73(4):1082–1087.
   PubMed Web of Science ®Google Scholar
• Iesalnieks I, Winter H, Bareck E, et al. Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients’ survival. Thyroid. 2008;18(6):615–624.
   PubMed Web of Science ®Google Scholar
• Muth A, Persson F, Jansson S, et al. Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol. 2010;36(7):699–704.
   PubMed Web of Science ®Google Scholar
• Grassi P, Verzoni E, Mariani L, et al. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer. 2013;11(4):484–488.
   PubMed Web of Science ®Google Scholar
• Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10(3):287–293.
   PubMed Web of Science ®Google Scholar
• Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol. 2003;10(6):705–710.
   PubMed Web of Science ®Google Scholar
• Thelen A, Jonas S, Benckert C, et al. Liver resection for metastases from renal cell carcinoma. World J Surg. 2007;31(4):802–807.
   PubMed Web of Science ®Google Scholar
• Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28(4):543–547.
   PubMed Web of Science ®Google Scholar
• Schwartz MJ, Smith EB, Trost DW, et al. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int. 2007;99(4):881–886.
   PubMed Web of Science ®Google Scholar
• Ginat DT, Saad WE, Turba UC. Transcatheter renal artery embolization: clinical applications and techniques. Tech Vasc Interv Radiol. 2009;12(4):224–239.
   PubMedGoogle Scholar
• Cornu JN, Roupret M, Lang H, et al. Kidney cancer management in 2007: news and recommendations. Prog Urol. 2008;18(suppl 4):S81–S87.
   PubMedGoogle Scholar
• Rodriguez Faba O, Akdogan B, Marszalek M, et al. Renal cancer working group of the Young Academic Urologists (YAU) working party of the European Association of Urology (EAU). Current status of focal cryoablation for small renal masses. Urology. 2016;90:9–15.
   PubMed Web of Science ®Google Scholar
• Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113(19):2671–2680.
   PubMedGoogle Scholar
• Park S, Cadeddu JA. Outcomes of radiofrequency ablation for kidney cancer. Cancer Control. 2007l;14(3):205–210.
   PubMedGoogle Scholar
• Dib RE, Touma NJ, Kapoor A. Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Can Urol Assoc J. 2009;3(2):143–149.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Saboorian MH, Duchene DA, et al. Nephrectomy after radiofrequency ablation-induced ureteropelvic junction obstruction: potential complication and long-term assessment of ablation adequacy. Urology. 2003;62(2):351–352.
   PubMed Web of Science ®Google Scholar
• Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):e549–e561.
   PubMed Web of Science ®Google Scholar
• Mennitto A, Verzoni E, Calareso G, et al. Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy. Tumori. 2017;103(1):15–21.
   PubMed Web of Science ®Google Scholar
• Rosenberg MD, Kim CY, Tsivian M, et al. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. Ajr. 2011;196(4):935–939.
   PubMed Web of Science ®Google Scholar
• Allaf ME, Varkarakis IM, Bhayani SB, et al. Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation–initial observations. Radiology. 2005;237(1):366–370.
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Sulman A, Solomon SB, et al. Percutaneous computerized tomography guided renal cryoablation using local anesthesia: pain assessment. J Urol. 2006;176(3):915–918.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Cizman Z, Hong K, et al. Prospective analysis of the safety and efficacy of percutaneous cryoablation for pT-1NxMx biopsy-proven renal cell carcinoma. Cardiovasc Intervent Radiol. 2011;34(3):573–578.
   PubMed Web of Science ®Google Scholar
• Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 2013;200(2):461–466.
   PubMed Web of Science ®Google Scholar
• Samarasekera D, Khalifeh A, Autorino R, et al. Percutaneous radiofrequency ablation versus percutaneous cryoablation: long-term outcomes following ablation for renal cell carcinoma. J Urol. 2013;189(4):e737–e738.
   Web of Science ®Google Scholar
• Dong X, Li X, Yu J, et al. Complications of ultrasound-guided percutaneous microwave ablation of renal cell carcinoma. Onco Targets Ther. 2016;9:5903–5909.
   PubMed Web of Science ®Google Scholar
• Kariniemi J, Ojala R, Hellström P, et al. MRI-guided percutaneous laser ablation of small renal cell carcinoma: initial clinical experience. Acta Radiol. 2010;51(4):467–472.
   PubMed Web of Science ®Google Scholar
• Nabi G, Goodman C, Melzer A. High intensity focused ultrasound treatment of small renal masses: clinical effectiveness and technological advances. Indian J Urol. 2010;26(3):331–337.
   PubMedGoogle Scholar
• Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34(1):251–266.
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–e177.
   PubMed Web of Science ®Google Scholar
• Teh B, Bloch C, Galli-Guevara M, et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J. 2007;3(1):e6.
   PubMedGoogle Scholar
• Gerszten PC, Burton SA, Ozhasoglu C, et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg. 2005;3(4):288–295.
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Shiu AS, Rhines LD, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1185–1192.
   PubMed Web of Science ®Google Scholar
• Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;48(5):1389–1393.
   PubMed Web of Science ®Google Scholar
• Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–1304.
   PubMed Web of Science ®Google Scholar
• Altoos B, Amini A, Yacoub M, et al. Local control rates of metastatic Renal Cell Carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015;10:218.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):15–124.
   Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412–1418.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–4265.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939.
   PubMed Web of Science ®Google Scholar
• Mennitto A, Grassi P, Ratta R, et al. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol. 2016;8(5):319–326.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol. 2016;17(7):917–927.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12(7):673–680.
   PubMed Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32(8):752–759.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Barrios CH, Alekseev B, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as firstline therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1378–1384.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, openlabel, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Ren M, et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4–e5.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(3):286–296.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Urun Y, McKay RR, et al. Cytoreductive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma. BJU Int. 2013;113(5b):E67–74.
   Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–874.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(6):804–834.
   Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl. 3):iii49–56.
   PubMed Web of Science ®Google Scholar